Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, Davis
University of Iowa
Washington University School of Medicine
M.D. Anderson Cancer Center
Mayo Clinic
BioMimetix JV, LLC
Thomas Jefferson University
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Big Ten Cancer Research Consortium
Stanford University
Fukushima Medical University
Emory University
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
University of Iowa
Ludwig Institute for Cancer Research
Humanetics Corporation
City of Hope Medical Center
Weill Medical College of Cornell University
EMD Serono
BioMimetix JV, LLC
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Fred Hutchinson Cancer Center
University of California, Davis
SCRI Development Innovations, LLC
University of Pittsburgh
M.D. Anderson Cancer Center
University of Cincinnati
UNC Lineberger Comprehensive Cancer Center
Dynavax Technologies Corporation
Eli Lilly and Company
Case Comprehensive Cancer Center
Daiichi Sankyo
NYU Langone Health
Abramson Cancer Center at Penn Medicine
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
Celgene
University of Kansas Medical Center
Dana-Farber Cancer Institute
Stanford University
NYU Langone Health
Icahn School of Medicine at Mount Sinai
Radiation Therapy Oncology Group
Memorial Sloan Kettering Cancer Center